These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 12482017)
1. Rebif offers another option for treating multiple sclerosis. Ryan M J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017 [No Abstract] [Full Text] [Related]
2. Multiple sclerosis and interferon beta-1b, past, present and future. Horowski R Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665 [No Abstract] [Full Text] [Related]
3. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Rice G Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173 [No Abstract] [Full Text] [Related]
4. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis. Murdoch D; Lyseng-Williamson KA Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455 [TBL] [Abstract][Full Text] [Related]
5. Shortcomings in pharmacy benefit forecasting--interferon beta products. Rich SJ; Meyer C J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461 [No Abstract] [Full Text] [Related]
6. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Hartung HP Expert Opin Pharmacother; 2009 Feb; 10(2):291-309. PubMed ID: 19236200 [TBL] [Abstract][Full Text] [Related]
7. Funding of drug treatment of multiple sclerosis should not be delayed. Paty DW BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903 [No Abstract] [Full Text] [Related]
9. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis. Chofflon M; Ben-Amor AF Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662 [No Abstract] [Full Text] [Related]
11. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis]. Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg]. Sumino R Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973 [No Abstract] [Full Text] [Related]
13. Beta interferon and multiple sclerosis: why the fuss? Mumford CJ QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337 [No Abstract] [Full Text] [Related]
14. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast. Bryant J; Clegg A; Milne R BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569 [No Abstract] [Full Text] [Related]
15. [A short history of beta-interferon therapy of multiple sclerosis]. Stock G; Horowski R Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113 [TBL] [Abstract][Full Text] [Related]
20. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis. Devonshire VA; Verdun di Cantogno E Ther Deliv; 2011 Nov; 2(11):1455-65. PubMed ID: 22844681 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]